NCT04305145View on ClinicalTrials.gov

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

June 30, 2030

Study Completion Date

June 30, 2030

Conditions
Melanoma Stage IIIMelanoma Stage IVSkin Cancer Stage IIISkin Cancer Stage IVDrug-Induced ColitisDrug ToxicityImmune-related Adverse Event
Interventions
DRUG

Infliximab

Infusion

DRUG

Methylprednisolone

Infusion

DRUG

Prednisone

Orally

Trial Locations (2)

02114

RECRUITING

Massachusetts General Hospital Cancer Center, Boston

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

lead

Massachusetts General Hospital

OTHER